Navamedic ASA · OSL:NAVA
Navamedic ASA — Q3 2021 Earnings Presentation
23 slides from Navamedic ASA's earnings presentation, November 2021
Slide 1: Third quarter results 2021
Q3 2021 Third quarter results 2021 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Highlights
Highlights Strong portfolio performance and growth Operations and sales Continued strong performance for Mysimba® and extended exclusive distribution rights in the Nordics. REVENUE GROSS MARGIN EBITDA Q3 63.6 MNOK 38.9% 3.7 MNOK Received conditional reimbursement for Mysimba® in Finland 2021 Up 12.0
Slide 3: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic ~ 30 professionals with Ambitious growth strategy, quality consumer health, countries, Baltics and strong local competence in high-potential pipeline and medical nutrition
Slide 4: Ambition of building a leading Nordic pharma company
Navamedic in brief Ambition of building a leading Nordic pharma company targeting growth in Northern Europe OUR MID-TERM TARGET 1 2 3 20% annual organic STRENGTHEN THE SECURE AND GROWTH THROUGH growth from 2021 with a CORE INCREASE THE M&A mid-term ambition VALUE THROUGH of building a 500 MNOK compa
Slide 5: Key portfolio developments
Key portfolio developments Continued growth for key products, further accelerated growth for Mysimba® MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA Medical nutrition products for Gastro, pain, urology, other Antibiotics, cardiology, Obesity & urology treatment of IEM* generics
Slide 6: Medical nutrition – Positive development across markets
Medical nutrition – Positive development across markets GROWTH DRIVERS Q3 2021 REVENUE • New products for PKU, 12.9 MNOK Ketogenic Diet and renal disease contributes to the (Q3 2020: 12.1 MNOK) growth • Stable sales in key areas IEM Products for treatment of Inborn Errors of Metabolism (IEM), a life
Slide 7: Consumer Health - launch of new and unique products
Consumer Health - launch of new and unique products GROWTH DRIVERS Q3 2021 REVENUE • Strong performance for ThermaCare® and Alflorex® 11.8 MNOK • Cysticina® and Zenflore® (Q3 2020: 9.1 MNOK) developed as planned 7
Slide 8: Branded Generics – Strong performance for the antibiotics portfolio
Branded Generics – Strong performance for the antibiotics portfolio GROWTH DRIVERS • Strong performance for the antibiotic portfolio. Q3 2021 REVENUE Tenders won in Finland 16.8 MNOK and a general Nordic tender (Norway and (Q3 2020: 20.2 MNOK) Denmark) • Slower sales for Imdur® due to out-of-stock s
Slide 9: Specialty pharma – continued strong growth
Specialty pharma – continued strong growth GROWTH DRIVERS • Mysimba® grew by around 77% in Q3 2021 Q3 2021 REVENUE compared to Q3 2020 • Extended exclusive 22.3 MNOK distribution rights for THE ONLY ORAL MEDICINE FOR TREATMENT OF OBESITY WITH DUAL MODE OF ACTION (Q3 2020: 15.0MNOK) Mysimba® in the N
Slide 10: Financials
FINANCIALS @ Navamedic
Slide 11: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures In Q3 2021, revenues grew by 12% compared to the same quarter last (in NOK '1000) Q3 2021 Q3 2020 YTD 2021 YTD 2020 Year 2020 year, contributing to a YTD revenue Operating revenues 63 620 56 799 188 279 154 575 209 877 growth of 21.8% Gross profit
Slide 12: Assets
Financials The slight change in Goodwill is due to Assets currency effect (in NOK '1000) 30.09.2021 30.09.2020 31.12.2020 Increase in Other intangible assets is Goodwill 62 288 64 802 64 472 due to the acquisition/booking of the marketing authorizations related to Deferred tax assets 9 168 9 242 9 1
Slide 13: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.09.2021 30.09.2020 31.12.2020 Equity ratio of 47.1%. Total equity 147 566 134 146 129 486 Non-current license liabilities 8 752 8 368 3 343 Increase in Equity is mainly due to Loans and borrowings 19 994 21 002 20 870 share premium from ACS share i
Slide 14: Cash flow Group – total operations
Financials Cash flow Group – total operations YTD YTD Year (in NOK '1000) Q3 2021 Q3 2020 2021 2020 2020 The cash flow from Operating Activities is due to Net profit Net cash flow from operating activities 4 172 -6 299 -12 585 -18 016 -3 180 coupled with changes in Net Working Capital Net cash flow
Slide 15: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 16: Summary and outlook
Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In Q3 2021, we have • Strengthened the core by driving underlying growth in the existing portfolio • Secured conditional reimbursement for Mysimba® in Finland • Continued our push for growt
Slide 17: Q&A
Q&A @ Navamedic
Slide 18: Thank you for your attention!
Thank you for your attention! Navamedic’s full-year and Q4 2021 presentation will be on 17th of February 2022
Slide 19: Appendix
APPENDIX @ Navamedic
Slide 20: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q3 2021 Q3 2020 YTD 2021 YTD 2020 Year 2020 Operating revenues 63 620 56 799 188 279 154 575 209 877 Total revenue 63 620 56 799 188 279 154 575 209 877 Cost of materials -38 852 -39 164 -114 332 -106 560 -139 538
Slide 21: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q3 2021 Q3 2020 YTD 2021 YTD 2020 Year 2020 Cash flow from operating activities Profit before tax 342 -231 379 -12 035 -16 596 Adjusted for: Depreciation, amortization and impairment 1 430 1 011 4 152 2 740 3 659 Financial i
Slide 22: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 23: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any